Therapeutic options for patients with Hodgkin's disease and non-Hodgkin's lymphoma who relapse after autologous transplant.
Although autologous stem cell transplantation for Hodgkin's disease and non-Hodgkin's lymphoma has become a safe and effective therapy, relapses after transplant are common. Emerging data indicate that an increasing number of patients can be re-induced into durable complete remission. Conventional dose- salvage chemotherapy and single-agent monoclonal antibody treatment provided limited success, but combination chemotherapy-monoclonal antibody treatments, second autografts, and reduced-intensity conditioning allografts provide encouraging results. For some patients, the best strategy may consist of participation in phase I to II studies of novel agents. New strategies designed to prevent relapse after autograft include cytokine therapy such as interleukin-2 in combination with monoclonal antibodies and the use of autologous antilymphoma vaccines.
van Besien
Koen
K
University of Chicago, Section of Hematology/Oncology, Rm I 209, 5841 South Maryland Ave, Chicago, Illinois 60637, USA. kvbesien@uchicago.edu
Smith
Sonali
S
Lazarus
Hillard M
HM
D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control / Q000628:therapy*; D012074:Remission Induction / Q000379:methods; D033581:Stem Cell Transplantation